ALT Q4 2018 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena

ALTAltimmune, Inc.

$331M

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-7.8% YoY

Gross Profit

-$476,040-18.4% margin

Operating Income

-$27M-1056.4% margin

Net Income

-$25M-946.7% margin

EPS (Diluted)

$-2.58

QoQ Revenue Growth

-1.7%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$68,823

Balance Sheet

Total Assets

$55M

Total Liabilities

$6M

Stockholders' Equity

$48M

Cash & Equivalents

$34M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$3M	-7.8%
Gross Profit	-$476,040	-$2M	+71.2%
Operating Income	-$27M	-$13M	-117.6%
Net Income	-$25M	-$9M	-177.5%

Revenue Segments

Grant

$3M100%

License And Service

$4,9470%